Iksuda Therapeutics Ltd.
๐ฌ๐งUnited Kingdom
- Country
- ๐ฌ๐งUnited Kingdom
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.glythera.com
IKS014 in Advanced Solid Tumors That Express HER2
Phase 1
Recruiting
- Conditions
- Breast CancerGastric CancerGastroesophageal-junction Cancer
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Iksuda Therapeutics Ltd.
- Target Recruit Count
- 165
- Registration Number
- NCT05872295
- Locations
- ๐ฆ๐บ
Macquarie University, Sydney, New South Wales, Australia
๐ฆ๐บConcord Repatriation General Hospital Medical Oncology Clinical Trials Unit, Concord, New South Wales, Australia
๐ฆ๐บWestmead Hospital, Westmead, New South Wales, Australia
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1
Recruiting
- Conditions
- B-cell Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaMantle Cell LymphomaB-cell Lymphoma
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Iksuda Therapeutics Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT05365659
- Locations
- ๐ฆ๐บ
Royal Adelaide Hospital, Adelaide, South Australia, Australia
๐ฎ๐นLa Fondazione e l'Istituto di Candiolo, Candiolo, Italy
๐ฎ๐นIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milano, Italy
ยฉ Copyright 2025. All Rights Reserved by MedPath